AIQ Solutions earns new Category III CPT code for comprehensive lesion-level assessment of metastatic cancer

AIQ Solutions, a Madison-based imaging analytics company advancing precision response assessment in metastatic disease, announced that the American Medical Association (AMA) has approved a new Category III CPT^® code enabling clinicians and health systems to report and track use of AIQ’s technology for determining heterogeneity of treatment response across all lesions in patients with advanced metastatic cancer. The code is intended for use with AIQ’s TRAQinform IQ platform, a quantitative imaging solution that evaluates treatment response at the lesion level across a patient’s entire disease, supporting more informed, data-driven clinical decisions.

The Category III CPT code recognizes the expanding clinical value of lesion-level analytics in complex oncology care. Traditional response measures often fail to capture the varied ways individual tumors respond to therapy. By quantifying this heterogeneity, TRAQinform IQ can help clinicians:

• Identify nonresponding lesions earlier
• Adapt treatment strategies based on individual lesion behavior
• Improve clinical decision-making for late-stage, metastatic disease
• Advance research and multisite study consistency through standardized reporting

While approximately 1,400 different AI-enabled Software as a Medical Devices (SaMD) have been cleared by the FDA, fewer than 30 have received CPT codes – AIQ is now included among that significantly smaller subset.

“This CPT code represents a critical step toward broader clinical adoption of technology that can transform care for patients with advanced cancer,” said Eric Horler, President and CEO of AIQ Solutions. “By formally recognizing the unique analysis our platform provides, the AMA has helped pave the way for oncologists to access intelligence that can guide more timely and effective treatment decisions.”

As part of the Isthmus Project portfolio, AIQ Solutions exemplifies our mission to accelerate innovation that improves access, quality, and outcomes for patients while creating scalable, system-ready solutions. The Category III CPT code supports standardized reporting for AIQ’s technology in real-world practice and research—laying groundwork for multisite studies, new operational pathways, and, in time, the potential for direct reimbursement after demonstrating clinical utility.

“AIQ’s progress shows why we invest in tools that turn complex data into actionable insights. We’re proud to support AIQ in as they improve care for patients with advanced metastatic disease.” — Elizabeth Hagerman, PhD, Executive Director, Isthmus Project

About AIQ Solutions

AIQ Solutions develops quantitative imaging analytics that evaluate treatment response across the full burden of metastatic disease, enabling clinicians to visualize, quantify, and track lesion level changes over time. Its TraqInform IQ platform supports decision making in complex oncology care by surfacing differential response patterns across individual lesions.

References

• AIQ Solutions Announces a New Category III CPT Code for Determining Heterogeneity of Change Across All Lesions for Advanced Metastatic Cancer Used with TRAQinform IQ Technology (via PR Newswire)
• AIQ Solutions — Customized care for late-stage cancer patients (Isthmus Project company profile)